White paper peanut allergy

Abstract The current management of a primary IgE-mediated peanut allergy consists the two basic pillars “exposure prophylaxis” with avoidance allergen and “emergency therapy” short-term treatment an acute allergic reaction after accidental ingestion. Accidental reactions are common despite attempted avoidance. severity or even anaphylactic ingestion is difficult to assess prior reaction. In addition, thresholds may vary depending on accompanying augmentation factor. Therefore, every patient should receive individual dietary counseling as well instructions for use emergency kit structured education program (anaphylaxis group training), if necessary. For first time, since fall 2021 causal option drug oral immunotherapy will now be available 4‑ 17-year-old peanut-allergic children adolescents. protein defatted powder Arachis hypogaea L., semen (peanuts) leads desensitization good efficacy record acceptable safety profile. Other options different therapeutic approaches also under development probably expand range in coming years.